PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020
DAEJEON, South Korea, Nov. 16, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020. ...
PharmAbcine to participate at BIO-Europe 2020
DAEJEON, South Korea, Oct. 23, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will participate in the 26th Annual International BIO-Europe Partnering Conference which will be held digitally from October 26th to 29th. PharmAbcine's business development ...
PharmAbcine expands partnership with Samsung Biologics for PMC-403
DAEJEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular ...
PharmAbcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies at KSMO 2020
DAEJEON, South Korea, Sept. 14, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) today announced positive data from its two combination trials of olinvacimab, its leading clinical candidate in oncology, with MSD's pembrolizumab at the 13th Annual Meeting of the Korean Society of Medical O...
PharmAbcine signs a CMO contract with Binex so Binex can produce olinvacimab at its new 5,000L production line
DAEJEON, South Korea, Sept. 2, 2020 /PRNewswire/ -- PharmAbcine (KRX: 208340ks), a biotech company focusing on the development of antibody therapeutics, announcedon August 31 that it had signed a contract manufacturing organization(CMO) agreement with Binex, a leading biologics CDMO(Contract Dev...
PharmAbcine is presenting at the KSMO 2020
DAEJEON, South Korea, Sept. 2, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotechnology company in South Korea, announced today that onSeptember 4th, the company will present the interim data of its ongoing IO combo clinical trials at KSMO 2020. KSMO 2020 is the...
PharmAbcine announces the execution of a Material Cooperative Research and Development Agreement (MCRADA) with the NIH to evaluate the efficacy of PMC-403 to treat SCLS
DAEJEON, South Korea, Aug. 18, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a Materials Cooperative Research and Development Agreement (MCRADA) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in whic...
PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC
DAEJEON, South Korea, Aug. 3, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a research collaboration with Wuxi Shuangliang Biotechnology (SLBio) to evaluate the combination of each party's clinical candidate, olinvacimab and C-005, a3rd generation of EGFR inhibitor with s...
PharmAbcine Signs Long-term Contract Manufacturing Organization Agreement for Olinvacimab with Binex
DAEJEON, South Korea, June 26, 2020 /PRNewswire/ -- PharmAbcine (KRX: 208340) (CEO: Jin-san Yoo), biotech company focusing on the development of antibody therapeutics, announced on 18th that it had signed a contract manufacturing organization(CMO) agreement with biologics contract development ...
PharmAbcine execute an agreement with Thermo Fisher for the development and manufacturing of its next-generation immune checkpoint blockade, PMC-309 for Phase I
DAEJEON, South Korea, June 10, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Thermo Fisher Scientific for the development and manufacturing of PMC-309, a next-generation immune checkpoint blockade to treat cancer. Under this agreement, PharmA...
PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas
DAEJEON, South Korea, June 3, 2020 /PRNewswire/ -- PharmAbcine (KOSDAQ: 208340), a clinical-stage biotechnology company, announced today that the company entered into a license agreement with Wincal Biopharm ("Wincal"), a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the c...
